Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report.

CONCLUSION: Intermittent low-dose therapy with bevacizumab represents an effective and cost-efficient treatment option for transfusion-dependent patients with hereditary hemorrhagic telangiectasia. PMID: 27878613 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27878613?dopt=Abstract

Source: Wiener Klinische Wochenschrift - November 22, 2016 Category: Journals (General) Authors: Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, Greil R, Weiss L Tags: Wien Klin Wochenschr Source Type: research